Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
June 6, 2026Frontiers in MedicineOpen Access

Stress hyperglycemia ratio (SHR) and triglyceride-glucose index (TYG) associated with renal response to finerenone in diabetic kidney disease: a retrospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Do higher stress hyperglycemia ratio (SHR) and triglyceride-glucose (TyG) index predict worse renal outcomes in adults with diabetic kidney disease initiating finerenone therapy?

Population

387 adults with diabetic kidney disease (DKD) and CKD stages 1–4 who initiated finerenone therapy

Comparison

Highest tertile of stress hyperglycemia ratio… vs Lowest tertiles of stress hyperglycemia ratio…

Design

Cohort

Key result

Higher baseline stress hyperglycemia ratio (SHR) and triglyceride-glucose (TyG) index were associated with worse renal outcomes, with the highest SHR tertile having a HR of 2.52 for the composite renal endpoint.

Authors

ACAnqi ChenLZLiting ZouWSWei Sun

Discussion

Loading...

Member takes

Overview

Higher stress hyperglycemia ratio and triglyceride-glucose index are associated with worse renal outcomes and an attenuated response to finerenone in patients with diabetic kidney disease.

Key Points

  • This study investigates how stress hyperglycemia ratio and triglyceride-glucose index relate to renal outcomes in patients with diabetic kidney disease. The goal is to identify predictive biomarkers for renal response to finerenone therapy.
  • Retrospective cohort study involving 387 adults with diabetic kidney disease and chronic kidney disease stages 1–4 initiating finerenone therapy.
  • Primary endpoint was a composite of sustained ≥40% eGFR decline or progression to end-stage kidney disease.
  • Cox proportional hazards models were used to analyze the associations, adjusting for clinical covariates.
  • The primary endpoint was reached by 62 patients (16.0%).
  • Higher baseline SHR (T3) was associated with a 2.52-fold increased risk (95% CI 1.48–4.29; p = 0.001) for worse renal outcomes.
  • Higher baseline TyG (T3) had a 1.96-fold increased risk (95% CI 1.22–3.15; p = 0.006) compared to the lowest tertiles.

Study Design

Type

Cohort (n=387)

Multicenter

No

Structured PICO

Do higher stress hyperglycemia ratio (SHR) and triglyceride-glucose (TyG) index predict worse renal outcomes in adults with diabetic kidney disease initiating finerenone therapy?

P
Population
387 adults with diabetic kidney disease (CKD stages 1-4) initiating finerenone therapy, followed for a median of 17.8 months.
E
Exposure
Highest tertile (T3) of stress hyperglycemia ratio (SHR) and triglyceride-glucose (TyG) index
C
Comparator
Lowest tertiles of stress hyperglycemia ratio (SHR) and triglyceride-glucose (TyG) index
O
Outcome
Composite renal endpoint including sustained ≥40% eGFR decline or progression to end-stage kidney disease (ESKD)composite

Main Result

Hazard Ratio: 2.52 (95% CI 1.48–4.29)

p-value: p=0.001

Higher stress hyperglycemia ratio and triglyceride-glucose index are associated with worse renal outcomes and an attenuated response to finerenone in patients with diabetic kidney disease.

Limitations

  • Retrospective cohort study design limits the ability to establish causality
  • Study population was limited to patients initiating finerenone therapy, which may not be representative of all patients with DKD
  • Did not account for changes in SHR and TyG over time
  • Conducted at a single center, requiring external validation in other populations

Cite This Study

Chen et al. (2026) conducted a cohort in Diabetic kidney disease (n=387). Stress hyperglycemia ratio (SHR) vs. Lowest tertile (T1) was evaluated on Composite of sustained ≥40% eGFR decline or progression to ESKD (HR 2.52, 95% CI 1.48-4.29, p=0.001). Higher baseline stress hyperglycemia ratio (SHR) and triglyceride-glucose (TyG) index were associated with worse renal outcomes, with the highest SHR tertile having a HR of 2.52 for the composite renal endpoint.

synapsesocial.com/papers/6a23b94671a5da9775e75388https://doi.org/10.3389/fmed.2026.1802071
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Finerenone in diabetic kidney disease: Findings from a single-center retrospective observational study2026
  2. 2Predictive Value of Non-Traditional Lipid Parameters NHHR and the TyG Index for Rapid Kidney Function Decline in Diabetic Patients: A Longitudinal Cohort Study Based on CHARLS2026
  3. 3Association between the triglyceride-glucose index and major adverse cardiovascular events in patients with chronic kidney disease stages 3–42025
  4. 4Association Between the Triglyceride-Glucose Index and All-Cause Mortality Among Patients with Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study2025
  5. 5Early Efficacy and Safety of Finerenone on Type 2 Diabetes‐Related Chronic Kidney Disease: A Real‐World Observational Study in China2025